We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Connect Biopharma Holdings Inc | NASDAQ:CNTB | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.17 | 17.53% | 1.14 | 1.00 | 1.18 | 1.20 | 0.93 | 1.00 | 70,720 | 01:00:00 |
|
||||||
|
|
|
|
|
|
|
|
UNITED STATES |
|
||||
|
SECURITIES AND EXCHANGE COMMISSION |
|
||||
|
Washington, D.C. 20549 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FORM 6-K |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORT OF FOREIGN PRIVATE ISSUER |
|
||||
|
PURSUANT TO RULE 13a-16 OR 15d-16 |
|
||||
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934 |
|
||||
|
|
|
|
|
|
|
|
For the month of October 2023 |
|
||||
|
|
|
|
|
|
|
|
Commission File Number: 001-40212 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Connect Biopharma Holdings Limited |
|
||||
|
(Translation of registrant's name into English) |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12265 El Camino Real, Suite 350 |
|
||||
|
San Diego, CA 92130, USA |
|
||||
|
(Address of principal executive office) |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. |
|
||||
|
|
|
|
|
|
|
|
Form 20-F ☒ Form 40-F ☐ |
|
||||
|
|
|
|
|
|
|
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ |
|
||||
|
|
|
|
|
|
|
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ |
|
||||
|
||||||
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K |
|
On October 18, 2023, Derek DiRocco, Ph.D. tendered his resignation as a director of Connect Biopharma Holdings Limited (the “Company”), effective October 18, 2023. Dr. DiRocco’s resignation is not the result of any disagreement with the Company, including but not limited to, on any matter related to its operations, policies or practices. |
|
This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333-264340) and Form S-8 (File Nos. 333-254254 and 333-266006) of the Company, filed with the Securities and Exchange Commission, and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. |
|
SIGNATURES |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
|
Dated: October 20, 2023 |
|
|
|
|
|
|
|
|
CONNECT BIOPHARMA HOLDINGS LIMITED |
||||
|
|
By |
|
/s/ Steven Chan |
||
|
|
|
|
Name: |
|
Steven Chan |
|
|
|
|
Title: |
|
Chief Financial Officer |
1 Year Connect Biopharma Chart |
1 Month Connect Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
